MEMPHASYS LIMITED. — Investor Presentation 2008

Jun 18, 2008

==> picture [173 x 57] intentionally omitted <==

FOR IMMEDIATE RELEASE

SpermSep CS10 Recognised In Federal Parliament Presentation

SYDNEY, AUSTRALIA – 19 June, 2008 – NuSep (ASX: NSP) is pleased to advise the market that the SpermSep CS10 was included in the top 20 ARC funded research projects within the last 5 to 10 years.

Prof. John Aitken, from Newcastle University and the Scientific Advisor to Nusep, presented a talk entitled “Improving our Reproductive Future” at Graeme Clarke Outcomes Forum at Federal Parliament House Canberra. This meeting was attended by members of parliament and select invitees from Australia’s prestigious scientific community. A copy of this presentation is attached to this release.

Nusep is proud to be associated with Professor John Aitken whose research on the CS10 has now resulted in at least four live births using this technology.

Mr John Manusu, Managing Director of NuSep said, “We are honoured by the fact that the SpermSep CS10 was selected by the ARC as one of the best 20 research projects of the last five to ten years. The SpermSep has successfully completed its first clinical trial and the first commercial sale is expected early in the 2009 calendar year.”

Prof. Graeme Clarke is one of Australia’s most recognised scientists having invented the cochlear implant which forms the basis of Cochlear Ltd.

About NuSep

NuSep (ASX: NSP) is a publicly listed life sciences company that sells products into the global bioseparations market. The company has offices in both Sydney, Australia and Atlanta, USA.

With a 30 year heritage in biological separations, NuSep has forged a world class reputation for its innovative yet simple biological separation techniques including the world’s first IVF sperm separation device. In short NuSep has redefined the BioSeparations market through innovation and simplification.

NuSep’s world renowned research team has developed an extensive portfolio of patented products. In all, NuSep currently manufactures, distributes and sells 55 products to customers in the USA, Europe, Asia and Australia.

NuSep Products:

==> picture [13 x 10] intentionally omitted <==

==> picture [13 x 10] intentionally omitted <==

• Gels – NuSep offers two precast gel ranges: iGels, innovative gels including long life gels with a 2 year shelf life: and NuBlu, high quality gels at an everyday price.

• Separation Instruments – NuSep has developed two unique biological separation instruments. The first instrument released in February 2008 can separate biological samples into 8 fractions for use in the proteomic market. The second instrument

NuSep Ltd Postal Address Contact Details Email info@nusep.com 22 Rodborough Rd P.O. Box 6126 Telephone +61 2 8977 9000 Web www.nusep.com Frenchs Forest NSW 2086 Frenchs Forest NSW 2086 Facsimile +61 2 8977 9099 ABN 33 120 047 556

– 2 –

==> picture [13 x 10] intentionally omitted <==

separates sperm for fertility treatments such as IVF and is presently undergoing clinical trials and is supported by a $2.2m AusIndustry Commercial Ready Grant. Biological Products – NuSep supplies research grade biological products manufactured using its unique separation technologies. These products include human IgG and Albumin.

For more information about NuSep please visit the company’s website www.NuSep.com

Contact: Prakash Patel Chief Financial Officer & Company Secretary +61 2 8977 9000 prakash.patel@nusep.com

==> picture [721 x 373] intentionally omitted <==

----- Start of picture text -----

Improving the Safety of Assisted Conception:
An ARC-AusIndustry collaboration
----- End of picture text -----

R. John Aitken and NuSep

ARC Centre of Excellence for Biotechnology and Development

The University of Newcastle, Australia.

==> picture [103 x 37] intentionally omitted <==

==> picture [87 x 34] intentionally omitted <==

==> picture [145 x 55] intentionally omitted <==

==> picture [530 x 47] intentionally omitted <==

Assisted Reproductive Technology (ART)

==> picture [667 x 367] intentionally omitted <==

----- Start of picture text -----

IVF ICSI
Assisted conception
IVF first baby: Louise Brown 1978
Patrick Steptoe and Bob Edwards
X X
----- End of picture text -----

==> picture [530 x 43] intentionally omitted <==

Contribution of ART to Australasian population

==> picture [681 x 374] intentionally omitted <==

----- Start of picture text -----

60000 400 R [2] = 0.989 AIHW National Perinatal Statistics Unit
Frost and Sullivan
300
50000
200
40000
100
30000
Year
•
Fertility in Australia is low, one in 4 woman
20000 remaining childless at the end of their reproductive
lives.
10000 •
One in every 35 babies produced by ART
Year
1990 1995 2000 2005 2010
20002002 2004 20062008 20102012
Revenue ($ Million)
Cycles started
----- End of picture text -----

==> picture [530 x 4] intentionally omitted <==

==> picture [530 x 47] intentionally omitted <==

Significance of male infertility

==> picture [331 x 299] intentionally omitted <==

----- Start of picture text -----

AIHW National Perinatal Statistics Unit Data 2004
Fertility Society of Australia
Fertility Society of Australia
----- End of picture text -----

• One in 20 Australian males is infertile

• Male infertility is the single largest

• defined cause of human infertility

DNA damage in the male germ line

==> picture [392 x 246] intentionally omitted <==

----- Start of picture text -----

TUNEL
COMET
90 55
50
80
45
70
40
60
35
50 30
25
40
20
30
15
20
10
10 5
0 0
Donors Patients Donors Patients
TUNEL (%)
Median tail DNA
----- End of picture text -----

==> picture [159 x 135] intentionally omitted <==

----- Start of picture text -----

TUNEL
----- End of picture text -----

==> picture [143 x 134] intentionally omitted <==

----- Start of picture text -----

COMET
----- End of picture text -----

==> picture [530 x 47] intentionally omitted <==

Reproductive consequences of DNA damage in the male germ line

• Impaired fertilization

• Disrupted preimplantation development

• Reduced pregnancy rates following natural or

• assisted conception

• Increased rates of abortion

• Increased rates of disease in children and young

• adults

==> picture [530 x 47] intentionally omitted <==

Spermsep CS10 System Schematics – Sperm Cell Separation

==> picture [362 x 28] intentionally omitted <==

==> picture [362 x 28] intentionally omitted <==

==> picture [362 x 28] intentionally omitted <==

==> picture [362 x 28] intentionally omitted <==

==> picture [362 x 28] intentionally omitted <==

==> picture [362 x 28] intentionally omitted <==

==> picture [362 x 28] intentionally omitted <==

==> picture [349 x 66] intentionally omitted <==

==> picture [349 x 66] intentionally omitted <==

==> picture [530 x 47] intentionally omitted <==

Electrophoretic sperm isolation

==> picture [619 x 304] intentionally omitted <==

----- Start of picture text -----

Sperm recovery DNA damage
30 20
25
16
20
12
15
8
10
4
5
0 0
30 60 120 300 600 900 Original Separated Residual
Duration of electrophoresis (sec) Treatment
/ml)
6
TUNEL (%)
Sperm concentration (10
----- End of picture text -----**

nature

International weekly journal of science

==> picture [530 x 4] intentionally omitted <==

==> picture [530 x 47] intentionally omitted <==

Industry - Centre of Excellence Partnership

• NuSep established Spermgen to develop CoE IP in Assisted Reproduction Technologies

==> picture [104 x 71] intentionally omitted <==

• Product development underway

• innovative sperm isolation procedures

• non-invasive assessment of oocyte & embryo quality

• International solutions for Assisted Conception Industry

==> picture [103 x 37] intentionally omitted <==

==> picture [87 x 34] intentionally omitted <==

==> picture [145 x 55] intentionally omitted <==